Please provide your email address to receive an email when new articles are posted on . Beta-blockers more effectively reduce risk for death or hospitalization in people with HFpEF compared with ...
New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...
New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...
Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced ...
A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, “Benidipine calcium channel blocker ...
Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...
Please provide your email address to receive an email when new articles are posted on . An ongoing study showed improvements in SSc severity, disease-related pain, Raynaud’s symptoms and ...
NEW YORK, July 31 (Praxis Press) Cardiovascular outcomes have not been compared in hypertensive patients treated with calcium channel blockers and in patients treated with older drugs. Hansson and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results